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Abstract
OBJECTIVE: To evaluate the efficacy and safety of
Danqipiantan capsule (DPC) for the treatment of
stroke.
METHODS: PubMed, China Science And Technolo-
gy Journal Database, Wanfang Database, Chinese
periodicals in the China National Knowledge Infra-
structure, and the General Hospital of Tianjin Medi-
cal University's Library were searched until July
2012. Randomized controlled trials (RCTs) and ob-
servational studies that reported the use of DPC for
treatment of stroke were selected.
RESULTS: Eleven articles that included 12 RCTs,
and 2 articles that included 3 observational studies
were identified. A total of 2590 patients participat-
ed in the studies. We found that there was a signifi-
cant statistical difference between DPC treatment
groups and the control groups in terms of the effec-
tive rate [risk ratio (RR), 1.14; 95% confidence inter-
vals (CI), 1.04, 1.25; P=0.01], Fugl-Meyer Assessment
Scale [weighted mean difference (WMD), 9.77; 95%
CI (4.84, 14.70); P=0.00], Barthel Index [WMD=6.40;
95% CI (3.15, 9.65)], and mean flow velocity [WMD=
5.79; 95% CI (1.64, 9.94)]. There were no significant
differences for The National Institutes of Health
Stroke Scale [WMD=0.60; 95% CI (﹣1.09, 2.29)], vi-
sual field defects [left visual field: WMD=﹣203.10;
95% CI (﹣424.41, 18.21); right visual field:WMD=﹣
172.60; 95% CI (﹣409.29, 64.09)] or the functional
independence measure [WMD=﹣7.90; 95% CI (﹣
16.64, 0.84)]. Seven articles that included eight
RCTs reported the safety of DPC treatment. Two ar-
ticles that included three observational studies also
reported beneficial effects for DPC. Because the
Chinese studies were of poor methodological quali-
ty, and most of the sample sizes were small, our
analysis was likely affected by bias.
CONCLUSION: DPC has a beneficial effect and is
relatively safe when used for the treatment of
stroke.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Stroke is one of the major diseases that lead to physical
disability and death worldwide.1 Approximately 2 mil-
lion people are diagnosed with stroke each year in China2
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and many individuals that survive from stroke are per-
manently disabled. More effective drugs for the treat-
ing stroke are needed. Danqipiantan capsule (DPC), a
new drug licensed in China, is used for the treatment
of stroke. DPC comprises nine herbal [Huangqi (Radix
Astragali Mongolici), Danshen (Radix Salvia Miltiorrhi-
zae), Chishao (Radix Paeoniae Rubra), Chuanxiong
(Rhizoma chuanxiong), Danggui (Radix Angelicae Sinen-
sis), Taoren (Semen Persicae), Honghua (Flos Carthami),
Yuanzhi (Radix Polygalae), and Shichangpu (Rhizoma
Acori Tatarinowii)], and five animal components [Ling-
yangjiao (Cornu Saigae Tataricae), Quanxie (Scorpio),
Shuizhi (Hirudo), Tubiechong (Eupolyphaga) and Ni-
uhuang (Calculus Bovis)].3 It has been approved for use
in seven countries.4 Recently, more and more studies
have reported the efficacy and safety of DPC, but they
were lack of an evidence-based medicine's support.
The aim of this study was to perform a systematic re-
view to evaluate the efficacy and safety of DPC.
MATERIALS ANDMETHODS
Eligibility criteria
The following criteria were used for choosing the stud-
ies included in the review: (a) randomized controlled
trials (RCTs) of DPC in stroke patients with random
sequence generation; (b) efficacy and safety studies that
compared DPC with Western Medicine, or with other
therapies; (c) studies that assessed outcomes using ap-
proved measures, such as the Fugl-Meyer assessment
(FMA), the Barthel index (BI), mean flow velocity
(MFV) of the bilateral middle cerebral artery, the Na-
tional Institutes of Health Stroke Scale (NIHSS), visu-
al field defects, functional independence measure
scores (FIM), the modified Rankin scale (mRS), or lab-
oratory tests; (d) stroke as defined according to interna-
tional criteria; (e) language restricted to English or Chi-
nese. Observational studies of the safety and efficacy of
DPC were also eligible. Only RCTs and observational
studies were used in the assessment. Letters, disserta-
tions, abstracts, and case reports were excluded.
Literature retrieval
Computerized literature search was performed by two
authors independently in the following databases:
PubMed, China Science and Technology Journal Data-
base, Wanfang Database, Chinese periodicals in the
China National Knowledge Infrastructure, and the
General Hospital of Tianjin Medical University's Li-
brary. The search was completed in July 2012. The
Chinese search term used was "Danqipiantan capsule",
while the English search terms were "MLC601",
"MLC901", "DPC", and "NeuroAid".
Study selection
Two authors examined all the searched results. The
first step was to exclude overlaps of titles. The titles
and abstracts were then reviewed to make sure all arti-
cles were about DPC for treating stroke. In case of dis-
crepancies between the reviewers' decisions about
whether to include a study, the original article was
jointly reevaluated. During the final round of review,
the full articles were read, and the final choices were
made.
Data collection process and data items
We independently extracted information from selected
studies according to pre-designed criteria. The items
for assessment included efficacy, FMA, BI, MFV, NI-
HSS, visual field defects, FIM, mRS, adverse events
(AEs), and laboratory tests.
Risk of bias assessment
Except for observational studies, we assessed the quali-
ty of every RCT in accordance with the Cochrane
Handbook for Systematic Reviews of Interventions,
Version 5.1.0 (Cochrane Information Management
System team).5 The Cochrane classification (selection
bias, performance bias, detection bias, attrition bias, re-
porting bias, and other biases) was applied to evaluate
the risk of bias.6 Selection bias refers to random meth-
ods and allocation concealment. Performance and de-
tection bias refers to blinding of participants, person-
nel, and outcome assessment. Reporting bias refers to
selective reporting. Other bias refers to withdrawals /
dropouts and baseline characteristics. In our analysis,
the studies of high quality, with a low risk of bias, were
the studies that met at least four of the seven Cochrane
classification criteria. The remaining studies were con-
sidered to be low quality, with a high risk of bias. Any
discrepancy in quality assessment was addressed with a
joint reexamination of the original articles.
Summary measures and synthesis of results
The data were analyzed by RevMan software (version
5.1; Nordic Cochrane Centre, Copenhagen, Den-
mark). A value of P<0.05 was considered to be statisti-
cally significant. The results were described qualitative-
ly for the studies that were not suitable for meta-analy-
sis. Risk ratios (RR) with 95% confidence intervals
(CI) were estimated for enumerated data and weighted
mean differences (WMD) with 95% CI were estimated
for continuous data. An I2 index value≥50% indicated
significant heterogeneity. A random-effects model was
used for the calculation of the pooled estimate to re-
duce bias caused by significant heterogeneity; if not, a
fixed-effects model was used.7 For every assessed item,
if two or more trials were included, totals and subtotals
were used and a detailed analysis using forest plots was
performed. Otherwise, the totals and subtotals were re-
moved.
RESULTS
Study selection
We identified 87 articles during the initial search. For-
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ty-six overlaps were excluded by scanning the titles.
The titles and abstracts were then scanned and 16 arti-
cles about the DPC for treating stroke were selected.
The full texts of these 16 articles were read in detail.
And final selection consisted of 11 articles3,8,10-18 repre-
senting 12 RCTs and 2 articles9,10 representing 3 obser-
vational studies (i.e., 12 articles) (Figure 1).
Study characteristics
The main characteristics of the included studies are pre-
sented in Table 1. One observational study evaluated
the effect of DPC (NeuroAid, MLC601) treatment.9
One article presented three trials.10 Two of the trials
were observational studies examining the safety of
DPC in healthy volunteers and patients. The third trial
compared DPC plus aspirin with aspirin only, in
stroke patients. One trial compared DPC plus acu-
puncture and Western Medicine with acupuncture
plus Western Medicine.8 One trial compared DPC
with Troxerutin.10 One trial compared MLC601 with
piracetam.17 Two articles compared DPC with Bu-
changnaoxintong.11,14 One of these articles reported re-
sults of two RCTs.14 The remaining five trials com-
pared NeuroAid (MLC601) with a placebo.3,13,15,16,18
The total number of the recruited participants
ranged from 10 to 1100 and they received treatment
from 8 h to 12 weeks. Four trials reported the effec-
tive rate,8-11 two trials reported FMA,3,15 five articles
reported degree of neural functional recovery,8,9,14,15,18
two trials reported NIHSS,15,18 two trials reported BI
and reported mRS,16,18 and five articles reported safe-
ty observations.11-14,18 One article reported FIM,15 one
provided data on visual field defects recovery,17 one
reported mini-mental state examination (MMSE) re-
sults,18 one reported information on intracranial he-
matoma reabsorption,8 one reported MFV,16and eight
articles reported adverse events3,11-17 (Table 1).
Risk of bias assessment
Eleven of the included articles described random se-
quence generation methods.3,8,10-18 Two articles reported
the methods of allocation concealment.14,18 Five articles
were participants and personnel blinding,3,14-16,18 and
five articles were outcome assessment.12,14,16,18 Six articles
mentioned withdrawals and dropouts.3,13-17 One article
described selective reporting.11 Two articles did not re-
Publications excluded after reading
the titles and abstracts written in
English (n=19): pharmacological ar-
ticles (n=9); advertisements (n=2);
certification (n=1); research record
(n=1); interview (n=1); Microorgan-
ism investigation (n=1); DPC as the
control (n=1); letter (n=1); tech-
nique generalization (n=1); other
capsule (n=1)
Initially identified articles (n=87):
published in Chinese (n=62); pub-
lished in English (n=25)
Excluded overlaps after reading
the titles published in English
(n=10)
Excluded overlaps after reading
the titles published in Chinese
(n=36)
Publications excluded after read-
ing the titles and abstracts written
in English (n=6): letter (n=1); re-
view articles (n=2); mechanism re-
search (n=1); animal experiments
(n=2)
The remaining articles (n=41)
The remaining articles for fur-
ther selection (n=16)
Publications excluded after reading the
full texts written in English (n=1): cohort
study (n=1) Publications excluded after reading thefull texts written in Chinese (n=3): cohort
studies (n=2); not standard observational
study (n=1)The eligible articles finally included (n=12):
published in English (n=8); published in Chi-
nese (n=4)
Figure 1 Flow chart of the trial selection process
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port having similar baseline characteristics.10,18 To sum-
marize, eight articles3,12-18 were of high methodological
quality with a low risk of bias, while the others8,9,10,11
had relatively poor methodological quality with a high
risk of bias (Table 2).
Efficacy
Data for effective rate was available in three articles,8,10,11
which included 258 participants. The results were sig-
nificantly different [RR=1.14; 95% CI (1.04, 1.25); P=
0.01] (Figure 2A). Moreover, one observational study
without detailed data reported that DPC treatment re-
sults indicated promising efficacy.8
FMA
Two trials3,15 with a total of 190 patients compared
MLC601 with placebo and provided data on FMA.
The analysis revealed that there was a statistically sig-
nificant difference between the two groups [WMD=
9.77; 95% CI (4.84, 14.70); P=0.00] (Figure 2B).
Study
Harandi AA 20113
Li Z 20078
Sheng K 20089
Tang DC 200410
Tang Q 200311
Gan R 200812
Young SH 201013
Chen C 200914
Kong KH 200915
Reza BS 201116
Kavian G 201117
Venketasubramanian
N 200918
Cases of the
treatment
group
100
60
130
42
30
32, 22, 10
52
100; 300
20
40
20
1100
Cases of
the control
group
50
60
130
36
30
32, 22, 10
49
100; 105
20
40
20
-
Course of
treatment
3 month
12 week
2 month
60 day
4 week
8 hour;
8 hour;
4 week
3 month
1 month
8 week
3 month
3 month
3 month
Intervention
measure in the
treatment group
MLC601
Acupuncture
method of
inducing
rehabitation,
Western
Medicine, DPC
Acupuncture
method of
inducing
resuscitation,
DPC
DPC
DPC
DPC for healthy
people; DPC
plus aspirin for
healthy people;
DPC for patients
MLC601
DPC
MLC601
MLC601
MLC601
Neuroaid
Intervention
measure in the
control group
Placebo
Acupuncture
method of
inducing
rehabitation,
Western
medicine
Acupuncture
method of
inducing
resuscitation,
DPC
Troxerutin
Buchang
Naoxintong
DPC for
healthy people;
Aspirin for
healthy people;
DPC for
patients
Placebo
Buchang
Naoxintong
Placebo
Placebo
Piracetam
Placebo
Outcome measure
FMA, AEs
Efficacy, situation of
intracranial haematoma
absorptance , degree of
neuronal functional
recovery
Efficacy, degree of
neuronal functional
recovery
Efficacy
Safety, efficacy, AEs
Biochemical,
hematological,
hemostatic parameters.
Blood coagulation
function, complete
blood count, blood
biochemical
examination, ECG, AEs
Comprehensive
functional score,
NIHSS, FMA, AEs,
complete blood count,
liver and renal function
FMA, FIM, NIHSS,
AEs
MFV, BI, mRS, AEs
Visual field defects
recovery degree, AEs
mRS, NIHSS, BI,
MMSE, Complete
Blood Count, liver and
renal function, ECG
Notes: Sheng K et al 9conducted an observational study; Gan R et al 12 conducted 3 trials including 2 observational studies; Chen C et al 14
conducted 2 RCTs. AEs: adverse events; BI: barthel index; DPC: Danqipiantan capsule; ECG: electrocardiograph; FIM: functional inde-
pendence measure; FMA: fugl-meyer assessment scale; MFV: mean flow velocity; MMSE: mini-mental state examination; mRS: modified
Rankin scale; NIHSS: national institutes of health stroke scale.
Table 1 Characteristics of included studies
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NIHSS
Two trials15,18 discussed NIHSS. One trial15 that provid-
ed data on NIHSS included 40 patients and compared
MLC601 with a placebo. The other trial18 was incom-
plete, so it was excluded from the analysis. The two
groups were not statistically different [WMD=0.60;
95% CI (﹣1.09, 2.29)] (Figure 2C).
Restoration of visual field defect
One trial17 with 40 patients compared MLC601 with
piracetam and provided data on visual field defect. The
outcome at 3 months suggested that a trend was pres-
ent, but the difference was not statistically significant
for the left- [WMD=﹣ 203.10; 95% CI (﹣ 424.41,
18.21)] or right-side visual fields [WMD=﹣ 172.60;
95% CI (﹣409.29, 64.09)] (Figure 2D, 2E).
BI
Two trials16,18 reported BI. One trial16 recruited 80 pa-
tients, compared MLC601 with a placebo, and provid-
ed data on BI. One incomplete trial18 was excluded.
The results of the meta-analysis revealed that there was
more improvement in the MLC601 group [WMD=
6.40; 95% CI (3.15, 9.65)] (Figure 2F).
FIM
One trial15 that included 40 patients compared
MLC601 with placebo and provided data on FIM.
Pooled analysis revealed that the two groups were not
statistically different at 8 weeks after treatment [WMD=
﹣7.90; 95% CI (﹣16.64, 0.84)] (Figure 2G).
MFV
For MFV, pooled analysis of one trial16 that consisted
of 80 patients revealed that MLC601 was significant-
ly more effective than a placebo at 3 months
post-treatment [WMD=5.79; 95% CI (1.64, 9.94)]
(Figure 2H).
Other endpoints
Two articles16,18 presented data on mRS. Analysis of one
of the studies that included 80 patients and that com-
pared MLC601 with a placebo revealed that a signifi-
cant difference was present (P<0.001).16 Results of the
analysis of the other trial, which provided data on intra-
cranial hematoma absorption, revealed that the im-
provement in the DPC group was greater than it was
in the control group.8
AEs
Eight articles reported AEs.3,11-17 The symptoms were
described in four of the articles.3,15-17 Transient vomiting
and nausea were observed in two trials.3,14 In the study
by Kong et al 15 15 subjects reported 16 AEs. Seven sub-
jects that received NeuroAid experienced eight AEs,
while eight subjects that received a placebo experienced
eight AEs. These AEs were mild or moderate in severi-
ty. Four serious AEs (SAEs) that were reported in the
NeuroAid group included jaundice and recurrent
stroke. One SAE was reported in the placebo group
(perianal abscess). The SAEs were considered to be un-
related to the study medication. No deaths were report-
ed.15 One article reported two AEs that one of which
was non-traumatic epistaxis in the treatment group
and the other was gastro-intestinal upset in the placebo
group.16 One trial reported that AEs, including mild ab-
dominal discomfort, were observed in 10% of the
Included
study
Harandi
AA 20113
Li Z 20078
Tang DC
200410
Tang Q
200311
Gan R
200812
Young SH
201013
Chen C
200914
Kong KH
200915
Reza BS
201116
Ghandehari
K 201117
Venketasub
ram-anian
N 200918
Random
method
√
√
√
√
√
√
√
√
√
√
√
Allocation
concealment
×
×
×
×
×
×
√
×
×
×
√
Blinding of
participants
and
personnel
√
×
×
×
×
×
√
√
√
×
√
Blinding
of
outcome
assessment
×
×
×
×
√
×
√
×
√
√
√
Withdrawals
/dropouts
√
×
×
×
×
√
√
√
√
√
-
Selective
reporting
×
×
×
√
×
×
×
×
×
×
×
Baseline
characteristics
√
√
×
√
√
√
√
√
√
√
×
Quality
of the
studies
High
Poor
Poor
Poor
High
High
High
High
High
High
High
Risk
of
bias
Low
High
High
High
Low
Low
Low
Low
Low
Low
Low
Notes: Gan R et al 12 conducted 1 RCT; Chen C et al 14 conducted 2 RCTs. Sheng K et al 9 was removed because it was not RCT. RCT:
randomized controlled trial.
Table 2 Risk of bias assessment
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Figure 2 Forest plots of Danqipiantan capsule for treating stroke
A: Efficacy; B: FMA; C: NIHSS; D: Restoration of visual field defects (left visual field); E: Restoration of visual field defects (right visual
field); F: BI; G: FIM; H: MFV. BI: Barthel Index; CI: confidence intervals; FIM: functional independence measure; FMA: fugl-meyer as-
sessment scale; IV: inverse variance; MFV: mean flow velocity; M-H: Mantal-Haenszel; NIHSS: national institutes of health stroke
scale; SD: standard distribution.WMD: weighted mean difference.
A
B
C
D
G
H
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MLC601 group of patients. No patients were excluded
from the trial. Headache, drowsiness, and dizziness oc-
curred in 10% (2/20) of the piracetam group of pa-
tients, and one patient was excluded because of severe
headaches.17 One trial reported that SAEs occurred in
the MLC601 group and in the placebo group. There
was one death, and study treatments were permanently
discontinued in five patients. Only one SAE was con-
sidered to be related to the trial medication.13 Five tri-
als3,11-14 recorded the clinical laboratory evaluations, in-
cluding liver and kidney function, biochemical parame-
ters, electrocardiograph results, and hematological and
hemostatic parameters. All of the laboratory test results
confirmed the safety of DPC.
712
JTCM |www. journaltcm. com December 15, 2013 |Volume 33 | Issue 6 |
Li JS et al. / Systematic Review
DISCUSSION
DPC is a Traditional Chinese Medicine marketed in
China as Danqipiantan capsule and marketed interna-
tionally as NeuroAid,12,14,18 "MLC601",3,13,15-17 and
"MLC901 (NeuroAidⅡ)".19 There are some differenc-
es among the different products. They have been used
in different pharmacological experiments. The ingredi-
ents in MLC601 are the same as those in NeuroAid,
but five animal components have been removed from
MLC901. In this article, we mainly analyzed related
published studies to give more convincing evidence for
their efficacy and safety.
We included 11 articles with 12 RCTs3,8,10-18 and 2 arti-
cles representing 3 observational studies in our analy-
sis.9,12 Outcome measures for functional recovery from
stroke were assessed using NIHSS, FMA, mRS, BI and
FIM, The BI score and mRS20,21 were used to measure
performance and autonomy level in basic daily living
activities. MRS is often used to measure the degree of
disability or dependence in the daily activities of peo-
ple who have experienced a stroke. The BI scale con-
sists of 6 grades, with a maximum score of 100. A BI
score of 65 is a transition point at which the patient's
disability changes from assisted independence, to de-
pendence for essential personal care.1,23 In our review,
we confirmed that MLC601 is more effective than pla-
cebo in terms of BI and mRS.16 The review revealed
that MLC601 could enhance the performance of daily
activities. This improvement indirectly resulted from
an improvement in neurological function. Most impor-
tantly, the sooner a patient can regain independence in
daily activities, the lower the likelihood that depression
will occur and affect recovery.
MFV (cm/s) of the bilateral middle cerebral artery was
recorded using transcranial doppler ultrasonography.
Stimulating angiogenesis and microcirculation were an
interesting strategy to enhance neuroplasticity in post
brain-infarct patients. MLC601 has been demonstrat-
ed to stimulate neurogenesis.19 The one trial16 that ex-
amined the MFV supported that conclusion. More-
over, the results of two trials3,15 indicated that MLC601
is superior to placebo in terms of FMA. The results al-
so suggested that MLC601 has good tolerability and
helps recovery. All of the Chinese studies also con-
firmed that the total effective rate was positive for
DPC. Given their low methodological quality, the re-
sults may have been affected by bias, but there was no
difference between the DPC group and the control
group with regard to NIHSS, visual field defects, and
FIM.15
Of the 11 articles included in the analysis, 83,12-18 Eng-
lish studies were of high quality. This quality suggests
that the risk of bias was low and that the outcome
would be more acceptable to foreign researchers. In
terms of AEs, DPC was demonstrated to be relatively
safe. Studies have demonstrated that DPC's anti-in-
flammatory effects may be due to specific ingredients,
but this possibility needs further investigation. Specific
components that benefit the stroke patients should be
identified in future scientific studies.17
Because the Chinese studies were of poor methodologi-
cal quality and most of the sample sizes were small, our
review has likely been affected by bias. All trials that
did not include a full description were excluded, which
may have resulted in selection bias. More related stud-
ies are needed in the future. However, our analysis indi-
cated that DPC treatment has a positive effect on
stroke patients and patients experience very few AEs.
More related studies are needed in the future.
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